A bispecific antibody (BsAb), or specific monoclonal antibody (BsMAb) is an artificial protein comprised of fragments from two different antibodies. By virtue of the inclusion of two different antigen binding regions, a bispecific antibody is capable of recognizing and binding to two different antigens, or two different epitope on an antigen.
The global Bi-Specific Antibodies Therapy market size was valued at US$ 4323 million in 2023 and is forecast to a readjusted size of USD 21190 million by 2030 with a CAGR of 25.8% during review period.
Global Bi-Specific Antibodies Therapy key players include Roche, Amgen, Sanofi, Pfizer, Johnson & Johnson, etc. Global top five manufacturers hold a share over 95%.
North America is the largest market, with a share about 65%, followed by Europe and China, both have a share over 30 percent. In terms of product, IgG-Based Antibodies is the largest segment, with a share over 85%. And in terms of application, the largest application is Haemophilia, followed by Cancer, etc.
This report is a detailed and comprehensive analysis for global Bi-Specific Antibodies Therapy market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2024, are provided.
Key Features:
Global Bi-Specific Antibodies Therapy market size and forecasts, in consumption value ($ Million), 2019-2030
Global Bi-Specific Antibodies Therapy market size and forecasts by region and country, in consumption value ($ Million), 2019-2030
Global Bi-Specific Antibodies Therapy market size and forecasts, by Type and by Application, in consumption value ($ Million), 2019-2030
Global Bi-Specific Antibodies Therapy market shares of main players, in revenue ($ Million), 2019-2024
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Bi-Specific Antibodies Therapy
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Bi-Specific Antibodies Therapy market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Amgen, Sanofi, Pfizer, Johnson & Johnson, AstraZeneca, AbbVie, Lindis Biotech, MacroGenics, Inc, Genmab, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
麻豆原创 segmentation
Bi-Specific Antibodies Therapy market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segmentation
Bi-Specific Antibodies Therapy market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
麻豆原创 segment by Type
Fragment-Based Antibodies
IgG-Based Antibodies
麻豆原创 segment by Application
Cancer
Haemophilia
Other Non-Cancer Diseases
麻豆原创 segment by players, this report covers
Roche
Amgen
Sanofi
Pfizer
Johnson & Johnson
AstraZeneca
AbbVie
Lindis Biotech
MacroGenics, Inc
Genmab
Alphamab Co. Ltd
Akeso, Inc.
麻豆原创 segment by regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
South America (Brazil, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 13 chapters:
Chapter 1, to describe Bi-Specific Antibodies Therapy product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Bi-Specific Antibodies Therapy, with revenue, gross margin, and global market share of Bi-Specific Antibodies Therapy from 2019 to 2024.
Chapter 3, the Bi-Specific Antibodies Therapy competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2019 to 2030.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2019 to 2024.and Bi-Specific Antibodies Therapy market forecast, by regions, by Type and by Application, with consumption value, from 2024 to 2030.
Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Bi-Specific Antibodies Therapy.
Chapter 13, to describe Bi-Specific Antibodies Therapy research findings and conclusion.
Please Note - This is an on demand report and will be delivered in 2 business days (48 Hours) post payment.
1 麻豆原创 Overview
1.1 Product Overview and Scope
1.2 麻豆原创 Estimation Caveats and Base Year
1.3 Classification of Bi-Specific Antibodies Therapy by Type
1.3.1 Overview: Global Bi-Specific Antibodies Therapy 麻豆原创 Size by Type: 2019 Versus 2023 Versus 2030
1.3.2 Global Bi-Specific Antibodies Therapy Consumption Value 麻豆原创 Share by Type in 2023
1.3.3 Fragment-Based Antibodies
1.3.4 IgG-Based Antibodies
1.4 Global Bi-Specific Antibodies Therapy 麻豆原创 by Application
1.4.1 Overview: Global Bi-Specific Antibodies Therapy 麻豆原创 Size by Application: 2019 Versus 2023 Versus 2030
1.4.2 Cancer
1.4.3 Haemophilia
1.4.4 Other Non-Cancer Diseases
1.5 Global Bi-Specific Antibodies Therapy 麻豆原创 Size & Forecast
1.6 Global Bi-Specific Antibodies Therapy 麻豆原创 Size and Forecast by Region
1.6.1 Global Bi-Specific Antibodies Therapy 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
1.6.2 Global Bi-Specific Antibodies Therapy 麻豆原创 Size by Region, (2019-2030)
1.6.3 North America Bi-Specific Antibodies Therapy 麻豆原创 Size and Prospect (2019-2030)
1.6.4 Europe Bi-Specific Antibodies Therapy 麻豆原创 Size and Prospect (2019-2030)
1.6.5 Asia-Pacific Bi-Specific Antibodies Therapy 麻豆原创 Size and Prospect (2019-2030)
1.6.6 South America Bi-Specific Antibodies Therapy 麻豆原创 Size and Prospect (2019-2030)
1.6.7 Middle East & Africa Bi-Specific Antibodies Therapy 麻豆原创 Size and Prospect (2019-2030)
2 Company Profiles
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business
2.1.3 Roche Bi-Specific Antibodies Therapy Product and Solutions
2.1.4 Roche Bi-Specific Antibodies Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.1.5 Roche Recent Developments and Future Plans
2.2 Amgen
2.2.1 Amgen Details
2.2.2 Amgen Major Business
2.2.3 Amgen Bi-Specific Antibodies Therapy Product and Solutions
2.2.4 Amgen Bi-Specific Antibodies Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.2.5 Amgen Recent Developments and Future Plans
2.3 Sanofi
2.3.1 Sanofi Details
2.3.2 Sanofi Major Business
2.3.3 Sanofi Bi-Specific Antibodies Therapy Product and Solutions
2.3.4 Sanofi Bi-Specific Antibodies Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.3.5 Sanofi Recent Developments and Future Plans
2.4 Pfizer
2.4.1 Pfizer Details
2.4.2 Pfizer Major Business
2.4.3 Pfizer Bi-Specific Antibodies Therapy Product and Solutions
2.4.4 Pfizer Bi-Specific Antibodies Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.4.5 Pfizer Recent Developments and Future Plans
2.5 Johnson & Johnson
2.5.1 Johnson & Johnson Details
2.5.2 Johnson & Johnson Major Business
2.5.3 Johnson & Johnson Bi-Specific Antibodies Therapy Product and Solutions
2.5.4 Johnson & Johnson Bi-Specific Antibodies Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.5.5 Johnson & Johnson Recent Developments and Future Plans
2.6 AstraZeneca
2.6.1 AstraZeneca Details
2.6.2 AstraZeneca Major Business
2.6.3 AstraZeneca Bi-Specific Antibodies Therapy Product and Solutions
2.6.4 AstraZeneca Bi-Specific Antibodies Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.6.5 AstraZeneca Recent Developments and Future Plans
2.7 AbbVie
2.7.1 AbbVie Details
2.7.2 AbbVie Major Business
2.7.3 AbbVie Bi-Specific Antibodies Therapy Product and Solutions
2.7.4 AbbVie Bi-Specific Antibodies Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.7.5 AbbVie Recent Developments and Future Plans
2.8 Lindis Biotech
2.8.1 Lindis Biotech Details
2.8.2 Lindis Biotech Major Business
2.8.3 Lindis Biotech Bi-Specific Antibodies Therapy Product and Solutions
2.8.4 Lindis Biotech Bi-Specific Antibodies Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.8.5 Lindis Biotech Recent Developments and Future Plans
2.9 MacroGenics, Inc
2.9.1 MacroGenics, Inc Details
2.9.2 MacroGenics, Inc Major Business
2.9.3 MacroGenics, Inc Bi-Specific Antibodies Therapy Product and Solutions
2.9.4 MacroGenics, Inc Bi-Specific Antibodies Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.9.5 MacroGenics, Inc Recent Developments and Future Plans
2.10 Genmab
2.10.1 Genmab Details
2.10.2 Genmab Major Business
2.10.3 Genmab Bi-Specific Antibodies Therapy Product and Solutions
2.10.4 Genmab Bi-Specific Antibodies Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.10.5 Genmab Recent Developments and Future Plans
2.11 Alphamab Co. Ltd
2.11.1 Alphamab Co. Ltd Details
2.11.2 Alphamab Co. Ltd Major Business
2.11.3 Alphamab Co. Ltd Bi-Specific Antibodies Therapy Product and Solutions
2.11.4 Alphamab Co. Ltd Bi-Specific Antibodies Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.11.5 Alphamab Co. Ltd Recent Developments and Future Plans
2.12 Akeso, Inc.
2.12.1 Akeso, Inc. Details
2.12.2 Akeso, Inc. Major Business
2.12.3 Akeso, Inc. Bi-Specific Antibodies Therapy Product and Solutions
2.12.4 Akeso, Inc. Bi-Specific Antibodies Therapy Revenue, Gross Margin and 麻豆原创 Share (2019-2024)
2.12.5 Akeso, Inc. Recent Developments and Future Plans
3 麻豆原创 Competition, by Players
3.1 Global Bi-Specific Antibodies Therapy Revenue and Share by Players (2019-2024)
3.2 麻豆原创 Share Analysis (2023)
3.2.1 麻豆原创 Share of Bi-Specific Antibodies Therapy by Company Revenue
3.2.2 Top 3 Bi-Specific Antibodies Therapy Players 麻豆原创 Share in 2023
3.2.3 Top 6 Bi-Specific Antibodies Therapy Players 麻豆原创 Share in 2023
3.3 Bi-Specific Antibodies Therapy 麻豆原创: Overall Company Footprint Analysis
3.3.1 Bi-Specific Antibodies Therapy 麻豆原创: Region Footprint
3.3.2 Bi-Specific Antibodies Therapy 麻豆原创: Company Product Type Footprint
3.3.3 Bi-Specific Antibodies Therapy 麻豆原创: Company Product Application Footprint
3.4 New 麻豆原创 Entrants and Barriers to 麻豆原创 Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 麻豆原创 Size Segment by Type
4.1 Global Bi-Specific Antibodies Therapy Consumption Value and 麻豆原创 Share by Type (2019-2024)
4.2 Global Bi-Specific Antibodies Therapy 麻豆原创 Forecast by Type (2025-2030)
5 麻豆原创 Size Segment by Application
5.1 Global Bi-Specific Antibodies Therapy Consumption Value 麻豆原创 Share by Application (2019-2024)
5.2 Global Bi-Specific Antibodies Therapy 麻豆原创 Forecast by Application (2025-2030)
6 North America
6.1 North America Bi-Specific Antibodies Therapy Consumption Value by Type (2019-2030)
6.2 North America Bi-Specific Antibodies Therapy 麻豆原创 Size by Application (2019-2030)
6.3 North America Bi-Specific Antibodies Therapy 麻豆原创 Size by Country
6.3.1 North America Bi-Specific Antibodies Therapy Consumption Value by Country (2019-2030)
6.3.2 United States Bi-Specific Antibodies Therapy 麻豆原创 Size and Forecast (2019-2030)
6.3.3 Canada Bi-Specific Antibodies Therapy 麻豆原创 Size and Forecast (2019-2030)
6.3.4 Mexico Bi-Specific Antibodies Therapy 麻豆原创 Size and Forecast (2019-2030)
7 Europe
7.1 Europe Bi-Specific Antibodies Therapy Consumption Value by Type (2019-2030)
7.2 Europe Bi-Specific Antibodies Therapy Consumption Value by Application (2019-2030)
7.3 Europe Bi-Specific Antibodies Therapy 麻豆原创 Size by Country
7.3.1 Europe Bi-Specific Antibodies Therapy Consumption Value by Country (2019-2030)
7.3.2 Germany Bi-Specific Antibodies Therapy 麻豆原创 Size and Forecast (2019-2030)
7.3.3 France Bi-Specific Antibodies Therapy 麻豆原创 Size and Forecast (2019-2030)
7.3.4 United Kingdom Bi-Specific Antibodies Therapy 麻豆原创 Size and Forecast (2019-2030)
7.3.5 Russia Bi-Specific Antibodies Therapy 麻豆原创 Size and Forecast (2019-2030)
7.3.6 Italy Bi-Specific Antibodies Therapy 麻豆原创 Size and Forecast (2019-2030)
8 Asia-Pacific
8.1 Asia-Pacific Bi-Specific Antibodies Therapy Consumption Value by Type (2019-2030)
8.2 Asia-Pacific Bi-Specific Antibodies Therapy Consumption Value by Application (2019-2030)
8.3 Asia-Pacific Bi-Specific Antibodies Therapy 麻豆原创 Size by Region
8.3.1 Asia-Pacific Bi-Specific Antibodies Therapy Consumption Value by Region (2019-2030)
8.3.2 China Bi-Specific Antibodies Therapy 麻豆原创 Size and Forecast (2019-2030)
8.3.3 Japan Bi-Specific Antibodies Therapy 麻豆原创 Size and Forecast (2019-2030)
8.3.4 South Korea Bi-Specific Antibodies Therapy 麻豆原创 Size and Forecast (2019-2030)
8.3.5 India Bi-Specific Antibodies Therapy 麻豆原创 Size and Forecast (2019-2030)
8.3.6 Southeast Asia Bi-Specific Antibodies Therapy 麻豆原创 Size and Forecast (2019-2030)
8.3.7 Australia Bi-Specific Antibodies Therapy 麻豆原创 Size and Forecast (2019-2030)
9 South America
9.1 South America Bi-Specific Antibodies Therapy Consumption Value by Type (2019-2030)
9.2 South America Bi-Specific Antibodies Therapy Consumption Value by Application (2019-2030)
9.3 South America Bi-Specific Antibodies Therapy 麻豆原创 Size by Country
9.3.1 South America Bi-Specific Antibodies Therapy Consumption Value by Country (2019-2030)
9.3.2 Brazil Bi-Specific Antibodies Therapy 麻豆原创 Size and Forecast (2019-2030)
9.3.3 Argentina Bi-Specific Antibodies Therapy 麻豆原创 Size and Forecast (2019-2030)
10 Middle East & Africa
10.1 Middle East & Africa Bi-Specific Antibodies Therapy Consumption Value by Type (2019-2030)
10.2 Middle East & Africa Bi-Specific Antibodies Therapy Consumption Value by Application (2019-2030)
10.3 Middle East & Africa Bi-Specific Antibodies Therapy 麻豆原创 Size by Country
10.3.1 Middle East & Africa Bi-Specific Antibodies Therapy Consumption Value by Country (2019-2030)
10.3.2 Turkey Bi-Specific Antibodies Therapy 麻豆原创 Size and Forecast (2019-2030)
10.3.3 Saudi Arabia Bi-Specific Antibodies Therapy 麻豆原创 Size and Forecast (2019-2030)
10.3.4 UAE Bi-Specific Antibodies Therapy 麻豆原创 Size and Forecast (2019-2030)
11 麻豆原创 Dynamics
11.1 Bi-Specific Antibodies Therapy 麻豆原创 Drivers
11.2 Bi-Specific Antibodies Therapy 麻豆原创 Restraints
11.3 Bi-Specific Antibodies Therapy Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 Industry Chain Analysis
12.1 Bi-Specific Antibodies Therapy Industry Chain
12.2 Bi-Specific Antibodies Therapy Upstream Analysis
12.3 Bi-Specific Antibodies Therapy Midstream Analysis
12.4 Bi-Specific Antibodies Therapy Downstream Analysis
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
Roche
Amgen
Sanofi
Pfizer
Johnson & Johnson
AstraZeneca
AbbVie
Lindis Biotech
MacroGenics, Inc
Genmab
Alphamab Co. Ltd
Akeso, Inc.
听
听
*If Applicable.
